Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This eBook offers an overview of drug patents that were and are set to expire and highlights efforts by the FDA to stimulate the market for generics.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Some courts have invalidated AI-related patents where the claims and specification of the patent lacked sufficient specificity regarding the invention.
Clinical trials are a necessary part of the creation and marketing of new drugs, but the way we incentivize them contributes to our current system of exorbitant pricing.
As different strategies to address the drug-pricing crisis are discussed and considered, it is worth remembering that HHS already has the power necessary to reduce the costs for many patented, life-saving medicines through a provision of the Bayh-Dole Act of 1980.
Opternative's complaint against eyewear retailer Warby Parker alleges that Warby violated non disclosure agreements and trade secrets to develop a rival eye exam app.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The value of intellectual property in a startup cannot be ignored. It is axiomatic that technology startups are the most attuned to the value of IP to their business — some form of technology is usually the backbone of their business model.
Four companies from the UC-Berkeley side of the CRISPR patent interference case have signed an alliance to recognize each other's rights to the technology. The agreement highlights the potential for many companies to coexist in the expansive CRISPR field.